Ajiki Wakiko, Tsukuma Hideaki, Oshima Akira
Department of Cancer Control and Statistics, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan.
Jpn J Clin Oncol. 2004 Jan;34(1):50-4. doi: 10.1093/jjco/hyh003.
Survival of childhood cancer patients is often described in specialized hospitals and/or institutions, but not in the general population.
The trends and patterns of childhood cancer survival during 20 years were investigated using the Osaka Cancer Registry's data. The study subjects were 3443 reported cases diagnosed as having the first primary cancer between 1975 and 1994 at the ages of 0-14 years and who lived in Osaka Prefecture, excluding Osaka City. All childhood cancers were classified into 12 diagnostic groups according to the International Classification of Childhood Cancer based on the histology of the cancer. The 5 year relative survival was calculated by the Ederer II method.
The 5-year relative survival was 58% for all cancers. The survivals of retinoblastoma and kidney tumor patients were as high as 89 and 72%, respectively, whereas those of leukemia and liver tumor patients were as low as 45 and 47%, respectively. When divided into the first and second half-periods, the survival for all cancers was markedly improved from 48 to 68%. The survivals, especially for patients with leukemia, lymphoma, neuroblastoma, hepatoma and gonadal or embryonal tumors, were enhanced by >20% between the first and second half-periods. When these results were compared with those reported in England and Wales and the USA, however, the survivals for many diagnostic groups in Osaka were lower, except that for neuroblastoma.
The survivals of childhood cancer patients have been markedly improved in Japan, but this finding suggested that the introduction and practice of chemotherapy was insufficient.
儿童癌症患者的生存率通常在专科医院和/或机构中进行描述,而非在普通人群中。
利用大阪癌症登记处的数据调查了20年间儿童癌症生存的趋势和模式。研究对象为1975年至1994年间在大阪府(不包括大阪市)确诊为患有首例原发性癌症、年龄在0至14岁的3443例报告病例。根据国际儿童癌症分类,依据癌症组织学将所有儿童癌症分为12个诊断组。采用埃德勒二世方法计算5年相对生存率。
所有癌症的5年相对生存率为58%。视网膜母细胞瘤和肾肿瘤患者的生存率分别高达89%和72%,而白血病和肝肿瘤患者的生存率分别低至45%和47%。若分为前半期和后半期,所有癌症的生存率从48%显著提高至68%。在前半期和后半期之间,生存率尤其对于白血病、淋巴瘤、神经母细胞瘤、肝癌以及性腺或胚胎性肿瘤患者提高了超过20%。然而,当将这些结果与英格兰、威尔士和美国报告的结果进行比较时,大阪许多诊断组的生存率较低,神经母细胞瘤除外。
在日本,儿童癌症患者的生存率已显著提高,但这一发现表明化疗的引入和应用并不充分。